Protagonist Therapeutics, Inc. (PTGX)
Market: NASD |
Currency: USD
Address: 7707 Gateway Boulevard
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Show more
📈 Protagonist Therapeutics, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$68.42
-
Upside/Downside from Analyst Target:
26.89%
-
Broker Call:
22
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
<0%
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Protagonist Therapeutics, Inc.
| Date | Reported EPS |
|---|
| 2026-05-04 (estimated upcoming) | - |
| 2026-02-19 (estimated upcoming) | - |
| 2025-11-05 (estimated upcoming) | - |
| 2025-11-04 (estimated upcoming) | - |
| 2025-08-04 (estimated upcoming) | - |
| 2025-08-03 (estimated upcoming) | - |
| 2025-05-06 | -0.19 |
| 2025-05-04 | - |
| 2025-02-21 | 1.98 |
| 2024-11-07 | -0.54 |
| 2024-08-06 | -0.5 |
| 2024-08-05 | -0.5 |
| 2024-05-07 | 3.26 |
| 2024-05-06 | 3.26 |
| 2024-02-27 | 0.44 |
| 2024-02-26 | 0.44 |
| 2023-11-02 | -0.58 |
| 2023-11-01 | -0.58 |
| 2023-08-03 | -0.68 |
| 2023-08-02 | -0.68 |
| 2023-05-04 | -0.67 |
| 2023-05-03 | -0.67 |
| 2023-03-15 | -0.69 |
| 2023-03-14 | -0.69 |
| 2022-11-08 | -0.64 |
| 2022-11-07 | -0.64 |
| 2022-08-04 | -0.84 |
| 2022-08-03 | -0.84 |
| 2022-05-04 | -0.43 |
| 2022-05-03 | -0.43 |
| 2022-02-28 | -0.77 |
| 2022-02-27 | -0.77 |
| 2021-11-03 | -0.7 |
| 2021-11-02 | -0.7 |
| 2021-08-04 | -0.69 |
| 2021-08-03 | -0.69 |
| 2021-05-04 | -0.54 |
| 2021-05-03 | -0.54 |
| 2021-03-10 | -0.48 |
| 2021-03-09 | -0.48 |
| 2020-11-04 | -0.21 |
| 2020-11-03 | -0.21 |
| 2020-08-06 | -0.61 |
| 2020-08-05 | -0.61 |
| 2020-05-07 | -0.72 |
| 2020-05-06 | -0.72 |
| 2020-03-09 | -0.63 |
| 2019-11-05 | -0.61 |
| 2019-08-06 | -1.18 |
| 2019-05-07 | -0.58 |
| 2019-03-11 | -0.57 |
| 2018-11-05 | -0.38 |
| 2018-08-06 | -0.41 |
| 2018-05-08 | -0.36 |
| 2018-03-06 | -0.15 |
| 2017-11-05 | -0.29 |
| 2017-08-07 | -0.89 |
| 2017-05-09 | -0.84 |
| 2017-03-06 | -0.67 |
| 2016-11-13 | -0.87 |
| 2016-09-14 | -19.07 |
| 2016-08-11 | - |
📰 Related News & Research
No related articles found for "protagonist therapeutics".
